Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MyoKardia, Inc.
Paying $13.1bn for MyoKardia and its potential first-in-class HCM drug, BMS sees a blockbuster sales opportunity that it will grow gradually. MyoKardia team will be absorbed into BMS, Caforio says.
MyoKardia is building up its organization to prepare for commercialization of mavacamten, a potential first-in-class agent for obstructive hypertrophic cardiomyopathy.
Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.
The latest breakthrough therapy designation announcements from the Pink Sheet’s US FDA Performance Tracker
- In Vitro Diagnostics
Drug Discovery Tools